Coronary Artery Inflammation

Acute Coronary Syndromes, Third Edition: Revised and Expanded

Volumn , Issue , 2004, Pages 1-31

  Bhatt, Deepak L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33645287938     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780203025673-3     Document Type: Chapter

References (181)

1. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA; 2000;284:1549-1558.
2. Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation; 2002; 106:136-40.
3. Buffon A, Biasucci LM, Liuzzo G, D’Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med; 2002;347:5-12.
4. Rioufol G, Finet G, Ginon I, Andre-Fouet X, Rossi R, Vialle E, Desjoyaux E, Convert G, Huret JF, Tabib A. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation; 2002;106:804-8.
5. Cusack MR, Marber MS, Lambiase PD, Bucknall CA, Redwood SR. Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol; 2002;39:1917-23.
6. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov; 2003;2:15-28.
7. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature; 1998;391:591-4.
8. Elzey BD, Tian J, Jensen RJ, Swanson AK, Lees JR, Lentz SR, Stein CS, Nieswandt B, Wang Y, Davidson BL, Ratliff TL. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity; 2003; 19:9-19.
9. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med; 2002; 8:247-52.
10. Tamura N, Yoshida M, Ichikawa N, Handa M, Ikeda Y, Tanabe T, Handa S, Goto S. Shearinduced von Willebrand factor-mediated platelet surface translocation of the CD40 ligand. Thromb Res; 2002;108:311-5.
11. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med; 2003;348:1104-11.
12. Hermann A, Rauch BH, Braun M, Schror K, Weber AA. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets; 2001; 12:74-82.
13. Quinn M, Bhatt DL, Zidar F, Vivekananthan D, Chew DP, Ellis SG, Plow E, EJ T. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. American Journal of Cardiology; 2004;93:679-84.
14. Cipollone F, Ferri C, Desideri G, Paloscia L, Materazzo G, Mascellanti M, Fazia M, Iezzi A, Cuccurullo C, Pini B, Bucci M, Santucci A, Cuccurullo F, Mezzetti A. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation; 2003;108:2776-82.
15. Stumpf C, Lehner C, Eskafi S, Raaz D, Yilmaz A, Ropers S, Schmeisser A, Ludwig J, Daniel WG, Garlichs CD. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail; 2003;5:629-37.
16. Kopp CW, Steiner S, Nasel C, Seidinger D, Mlekusch I, Lang W, Bartok A, Ahmadi R, Minar E. Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting. Stroke; 2003;34:2560-7.
17. Schonbeck U, Gerdes N, Varo N, Reynolds RS, Horton DB, Bavendiek U, Robbie L, Ganz P, Kinlay S, Libby P. Oxidized low-density lipoprotein augments and 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation; 2002;106:2888-93.
18. Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, Falco A, Cuccurullo F, Davi G. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia:effects of statin therapy. Circulation; 2002;106:399-402.
19. Nannizzi-Alaimo L, Rubenstein MH, Alves VL, Leong GY, Phillips DR, Gold HK. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation; 2002;105:2849-54.
20. Wang CL, Wu YT, Liu CA, Lin MW, Lee CJ, Huang LT, Yang KD. Expression of CD40 ligand on CD4_ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. Pediatrics; 2003;111:E140-7.
21. Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, Fiocchi C. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut; 2003;52:1435-41.
22. Danese S, de la Motte C, Sturm A, Vogel JD, West GA, Strong SA, Katz JA, Fiocchi C. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology; 2003;124:1249-64.
23. Mallat Z, Gojova A, Brun V, Esposito B, Fournier N, Cottrez F, Tedgui A, Groux H. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation; 2003;108:1232-7.
24. Janket SJ, Baird AE, Chuang SK, Jones JA. Meta-analysis of periodontal disease and risk of coronary heart disease and stroke. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003;95:559-69.
25. Joshipura KJ, Hung HC, Rimm EB, Willett WC, Ascherio A. Periodontal disease, tooth loss, and incidence of ischemic stroke. Stroke; 2003;34:47-52.
26. Hung HC, Willett W, Merchant A, Rosner BA, Ascherio A, Joshipura KJ. Oral health and peripheral arterial disease. Circulation; 2003;107:1152-7.
27. Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs DR, Jr, Papapanou PN, Sacco RL. Relationship between periodontal disease, tooth loss, and carotid artery plaque:the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Stroke; 2003;34:2120-5.
28. Slade GD, Ghezzi EM, Heiss G, Beck JD, Riche E, Offenbacher S. Relationshipbetween periodontal disease and C-reactive protein among adults in the Atherosclerosis Risk in Communities study. Arch Intern Med; 2003;163:1172-9.
29. Amar S, Gokce N, Morgan S, Loukideli M, Van Dyke TE, Vita JA. Periodontal disease is associated with brachial artery endothelial dysfunction and systemic inflammation. Arterioscler Thromb Vasc Biol; 2003;23:1245-9.
30. Loos BG, Craandijk J, Hoek FJ, Wertheim-van Dillen PM, van der Velden U. Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. J Periodontol; 2000;71:1528-34.
31. Rexrode KM, Pradhan A, Manson JE, Buring JE, Ridker PM. Relationshipof total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol; 2003;13:674-82.
32. Christ-Crain M, Meier C, Guglielmetti M, Huber PR, Riesen W, Staub JJ, Muller B. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis; 2003;166:379-86.
33. Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, Giovannini L, Norpoth M, Metelli MR, Cristofani R, Bertelli AA, Sbragia G, Tetta C, Palla R. C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron; 2002;91:594-600.
34. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation; 2003;107:87-92.
35. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med; 2003;349:2399-406.
36. Shishehbor MH, Bhatt DL, Topol EJ. Using C-reactive protein to assess cardiovascular disease risk. Cleve Clin J Med; 2003;70:634-40.
37. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation; 2003;107:499-511.
38. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol.; 2003;41:37S-42S.
39. Zairis MN, Manousakis SJ, Stefanidis AS, Papadaki OA, Andrikopoulos GK, Olympios CD, Hadjissavas JJ, Argyrakis SK, Foussas SG. C-reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction. Am Heart J; 2002;144:782-9.
40. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E. Creactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol; 1998;31:1460-5.
41. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, Topol EJ, Ellis SG. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation; 2001;104:992-7.
42. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, Pestaner J, Smialek J, Virmani R. Elevated C-reactive protein values and atherosclerosis in sudden coronary death:association with different pathologies. Circulation; 2002;105:2019-23.
43. Alvarez Garcia B, Ruiz C, Chacon P, Sabin JA, Matas M. High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. J Vasc Surg; 2003; 38:1018-24.
44. Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M, Koenig W. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984- 1998. Arch Intern Med; 2003;163:93-9.
45. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. Jama; 2003;290:2945-51.
46. Bhatt DL, Topol EJ. The arterial inflammation hypothesis. Arch Intern Med; 2002;162:2249-51.
47. Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation; 2003;108:2292-7.
48. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation; 2003;107:398-404.
49. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation; 2002;106:913-9.
50. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-Reactive Protein and Complement Components in Atherosclerotic Plaques. Am J Pathol; 2001;158:1039-1051.
51. Hoffmeister HM, Ehlers R, Buttcher E, Kazmaier S, Szabo S, Beyer ME, Steinmetz A, Seipel L. Comparison of C-reactive protein and terminal complement complex in patients with unstable angina pectoris versus stable angina pectoris. Am J Cardiol; 2002;89:909-12.
52. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation; 2001;103:1194-7.
53. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V, Torzewski J. C-reactive protein in the arterial intima: role of Creactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol; 2000;20:2094-9.
54. Verma S, Badiwala MV, Weisel RD, Li SH, Wang CH, Fedak PW, Li RK, Mickle DA. Creactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: Implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg; 2003;126:1886-91.
55. Bhatt DL, Chew DP, Lincoff AM, Simoons ML, Harrington RA, Ommen SR, Jia G, Topol EJ. Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. Am J Cardiol; 2003;92:136-140.
56. Yen MH, Bhatt DL, Chew DP, Harrington RA, Newby LK, Ardissino D, Werf FV, White JA, Moliterno DJ, Topol EJ. Association between admission white blood cell count and oneyear mortality in patients with acute coronary syndromes. Am J Med; 2003;115:318-21.
57. Gurm HS, Bhatt DL, Lincoff AM, Tcheng JE, Kereiakes DJ, Kleiman NS, Jia G, Topol EJ. Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials. Heart; 2003; 89:1200-4.
58. Gurm HS, Bhatt DL, Gupta R, Ellis SG, Topol EJ, Lauer MS. Preprocedural white blood cell count and death after percutaneous coronary intervention. Am Heart J; 2003;146:692-8.
59. Aronow HD, Shishebor MH, Davis DA. White blood cell count predicts microembolic Doppler signals during carotid stenting: a link between inflammation and embolization. Circulation; 2002;106:II-577.
60. Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, Komatsu R, Ikura Y, Ogami M, Shimada Y, Ehara S, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation; 2002;106:2894-900.
61. Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Thomas JD, Topol EJ, Hazen SL, Penn MS. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J ExpMed; 2003;197:615-24.
62. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol; 2001;158:879-91.
63. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, Simoons ML, Hamm CW. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation; 2003;108:1440-5.
64. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med; 2003;349:1595-604.
65. Smith DA, Zouridakis EG, Mariani M, Fredericks S, Cole D, Kaski JC. Neopterin levels in patients with coronary artery disease are independent of Chlamydia pneumoniae seropositivity. Am Heart J; 2003;146:69-74.
66. Auer J, Berent R, Labetanig E, Eber B. Serum neopterin and activity of coronary artery disease. Heart Dis; 2001;3:297-301.
67. Garcia-Moll X, Coccolo F, Cole D, Kaski JC. Serum neopterin and complex stenosis morphology in patients with unstable angina. J Am Coll Cardiol; 2000;35:956-62.
68. Gurfinkel EP, Scirica BM, Bozovich G, Macchia A, Manos E, Mautner B. Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol; 1999;83:515-8.
69. Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis; 2003;41:1212-8.
70. Walter RB, Fuchs D, Weiss G, Walter TR, Reinhart WH. HMG-CoA reductase inhibitors are associated with decreased serum neopterin levels in stable coronary artery disease. Clin Chem Lab Med; 2003;41:1314-9.
71. Ikeda H, Ueyama T, Murohara T, Yasukawa H, Haramaki N, Eguchi H, Katoh A, Takajo Y, Onitsuka I, Ueno T, Tojo SJ, Imaizumi T. Adhesive interaction between P-selectin and sialyl Lewis(x) plays an important role in recurrent coronary arterial thrombosis in dogs. Arterioscler Thromb Vasc Biol; 1999;19:1083-90.
72. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation; 2001;103:491-5.
73. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation; 2000;102:2165-8.
74. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, McCabe CH, Cannon CP, Braunwald E. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation; 2003;107:690-5.
75. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med; 2000; 342:836-43.
76. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoproteinassociated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol; 2001;38:1302-6.
77. Beaudeux JL, Burc L, Imbert-Bismut F, Giral P, Bernard M, Bruckert E, Chapman MJ. Serum plasma pregnancy-associated protein A: a potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk. Arterioscler Thromb Vasc Biol; 2003;23:e7-10.
78. Ferroni P, Basili S, Martini F, Cardarello CM, Ceci F, Di Franco M, Bertazzoni G, Gazzaniga PP, Alessandri C. Serum metalloproteinase 9 levels in patients with coronary artery disease:a novel marker of inflammation. J Investig Med; 2003;51:295-300.
79. Nomoto K, Oguchi S, Watanabe I, Kushiro T, Kanmatsuse K. Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1. J Cardiol; 2003;42:201-6.
80. Maksimowicz-McKinnon K, Bhatt DL, Calabrese LH. Recent advances in vascular inflammation:C-reactive protein and other inflammatory biomarkers. Curr Opin Rheumatol; 2004;16:18-24.
81. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationshipbetween interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. Jama; 2001;286:2107-13.
82. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation; 2000; 101:1767-72.
83. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation; 2001; 104:746-9.
84. Anguera I, Miranda-Guardiola F, Bosch X, Filella X, Sitges M, Marin JL, Betriu A, Sanz G. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J; 2002;144:811-7.
85. Caligiuri G, Rudling M, Ollivier V, Jacob MP, Michel JB, Hansson GK, Nicoletti A. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med; 2003;9:10-7.
86. Waehre T, Halvorsen B, Damas JK, Yndestad A, Brosstad F, Gullestad L, Kjekshus J, Froland SS, Aukrust P. Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest; 2002;32:803-10.
87. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, Zeiher AM. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation; 2003;107:2109-14.
88. Bhatt DL, Mills R. The yin and yang of arterial inflammation. J Am Coll Cardiol; 2004;44:50-2.
89. Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Kubo N, Cheroutre H, Curtiss LK, Berliner JA, Boisvert WA. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ Res; 2002;90:1064-71.
90. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation; 2002;106:24-30.
91. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, Evans A, Cambien F, Tiret L. Interleukin-18 and the risk of coronary heart disease in European men: the Prospec tive Epidemiological Study of Myocardial Infarction (PRIME). Circulation; 2003;108:2453-9.
92. Yamaoka-Tojo M, Tojo T, Masuda T, Machida Y, Kitano Y, Kurosawa T, Izumi T. Creactive protein-induced production of interleukin-18 in human endothelial cells: a mechanism of orchestrating cytokine cascade in acute coronary syndrome. Heart Vessels; 2003;18:183-7.
93. Knoflach M, Kiechl S, Kind M, Said M, Sief R, Gisinger M, van der Zee R, Gaston H, Jarosch E, Willeit J, Wick G. Cardiovascular risk factors and atherosclerosis in young males:ARMY study (Atherosclerosis Risk-Factors in Male Youngsters). Circulation; 2003;108:1064-9.
94. Weitgasser R, Lechleitner M, Koch T, Galvan G, Muhlmann J, Steiner K, Hoppichler F. Antibodies to heat-shock protein 65 and neopterin levels in patients with type 1 diabetes mellitus. ExpClin Endocrinol Diabetes; 2003;111:127-31.
95. Maron R, Sukhova G, Faria AM, Hoffmann E, Mach F, Libby P, Weiner HL. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation; 2002;106:1708-15.
96. Harats D, Yacov N, Gilburd B, Shoenfeld Y, George J. Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am Coll Cardiol; 2002;40:1333-8.
97. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, Gokce N, Keaney JF, Jr, Penn MS, Sprecher DL, Vita JA, Hazen SL. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA; 2003;289:1675-80.
98. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Boger R. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol; 2002;13:490-6.
99. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation; 2002;105:1760-3.
100. Kaski JC, Cruz-Fernandez JM, Fernandez-Berges D, Garcia-Moll X, Martin Jadraque L, Mostaza J, Lopez Garcia-Aranda V, Gonzalez Juanatey JR, Castro Beiras A, Martin Luengo C, Alonso Garcia A, Lopez-Bescos L, Marcos Gomez G. [Inflammation markers and risk stratification in patients with acute coronary syndromes: design of the SIESTA Study (Systemic Inflammation Evaluation in Patients with non-ST segment elevation Acute coronary syndromes)]. Rev EspCardiol; 2003;56:389-95.
101. Stefanadis C, Diamantopoulos L, Vlachopoulos C, Tsiamis E, Dernellis J, Toutouzas K, Stefanadi E, Toutouzas P. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo: A new method of detection by application of a special thermography catheter. Circulation; 1999;99:1965-71.
102. Stefanadis C, Diamantopoulos L, Dernellis J, Economou E, Tsiamis E, Toutouzas K, Vlachopoulos C, Toutouzas P. Heat production of atherosclerotic plaques and inflammation assessed by the acute phase proteins in acute coronary syndromes. J Mol Cell Cardiol; 2000;32:43-52.
103. Blake GJ, Ostfeld RJ, Yucel EK, Varo N, Schonbeck U, Blake MA, Gerhard M, Ridker PM, Libby P, Lee RT. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma:an in vivo study with high-resolution MRI. Arterioscler Thromb Vasc Biol; 2003;23:e11-4.
104. Magyar MT, Szikszai Z, Balla J, Valikovics A, Kappelmayer J, Imre S, Balla G, Jeney V, Csiba L, Bereczki D. Early-onset carotid atherosclerosis is associated with increased intimamedia thickness and elevated serum levels of inflammatory markers. Stroke; 2003;34:58-63.
105. Papagianni A, Kalovoulos M, Kirmizis D, Vainas A, Belechri AM, Alexopoulos E, Memmos D. Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients. Nephrol Dial Transplant; 2003;18:113-9.
106. Cao JJ, Thach C, Manolio TA, Psaty BM, Kuller LH, Chaves PH, Polak JF, Sutton-Tyrrell K, Herrington DM, Price TR, Cushman M. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation; 2003;108:166-70.
107. Feng D, Tracy RP, Lipinska I, Murillo J, McKenna C, Tofler GH. Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolysis; 2000;9:37-41.
108. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation; 1999;100:793-8.
109. Feldman M, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol; 2001;37:2036-41.
110. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med; 1997;336:973-9.
111. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, Frederick B, Nakada MT, Topol EJ. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation; 2001;104:163-7.
112. Lenderink T, Boersma E, Heeschen C, Vahanian A, de Boer MJ, Umans V, van den Brand MJ, Hamm CW, Simoons ML. Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA. Eur Heart J; 2003;24:77-85.
113. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation; 2003;107:1123-8.
114. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multicenter randomized trials. Circulation; 2001;103:201-206.
115. Chew DP, Bhatt DL. Oral glycoprotein IIb/IIIa antagonists in coronary artery disease. Curr Cardiol Rep; 2001;3:63-71.
116. May AE, Kalsch T, Massberg S, Herouy Y, Schmidt R, Gawaz M. Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation; 2002;106:2111-7.
117. Chew DP, Bhatt DL, Robbins MA, Mukherjee D, Roffi M, Schneider JP, Topol EJ, Ellis SG. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol; 2001;88:672-4.
118. JK, Jeong MH, Lee KM, Bae HR, Lim YJ, Park KW, Cheon SM. Changes in platelet p-selectin and in platelet p-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. J Thromb Thrombolysis; 2002;14:145-50.
119. Klinkhardt U, Graff J, Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther; 2002;71:176-85.
120. Bhatt DL, Topol EJ. The Rationale and Design of the CHARISMA Trial. Am Heart J 2004:; In:press.
121. Wang L, Brown JR, Varki A, Esko JD. Heparin’s anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest; 2002; 110:127-36.
122. Montalescot G, Bal-dit-Sollier C, Chibedi D, Collet JP, Soulat T, Dalby M, Choussat R, Cohen A, Slama M, Steg PG, Dubois-Rande JL, Metzger JP, Tarragano F, Guermonprez JL, Drouet L. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol; 2003;91:925-30.
123. Cirino G, Cicala C, Bucci MR, Sorrentino L, Maraganore JM, Stone SR. Thrombin functions as an inflammatory mediator through activation of its receptor. J Exp Med; 1996;183:821-124.
124. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation; 1999;100:230-5.
125. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation; 2001;103:1191-1193.
126. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. Jama; 2001;286:64-70.
127. Miller YI, Chang MK, Binder CJ, Shaw PX, Witztum JL. Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol; 2003;14:437-45.
128. Bayes B, Pastor MC, Bonal J, Junca J, Hernandez JM, Riutort N, Foraster A, Romero R. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant; 2003;18:106-12.
129. Ansell BJ, Watson KE, Weiss RE, Fonarow GC. hsCRP and HDL Effects of Statins Trial (CHEST): Rapid Effect of Statin Therapy on C-Reactive Protein and High-Density Lipoprotein Levels A Clinical Investigation. Heart Dis; 2003;5:2-7.
130. van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis; 2003;166:129-35.
131. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, Ellis SG. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation; 2002;105:691-6.
132. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, Ellis SG. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation; 2003;107:1750-1756.
133. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Califf RM, Ohman EM, Kleiman NS, Keltai M, Wilcox RG, Vahanian A, Armstrong PW, Lauer MS. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes:an observational study. Lancet; 2001;357:1063-8.
134. Aronow HD, Novaro GM, Lauer MS, Brennan DM, Lincoff AM, Topol EJ, Kereiakes DJ, Nissen SE. In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. Arch Intern Med; 2003;163:2576-82.
135. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol; 2003;92:17K-22K.
136. Sager PT, Melani L, Lipka L, Strony J, Yang B, Suresh R, Veltri E. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol; 2003;92:1414-8.
137. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation; 2003;107:2409-15.
138. KashyapML, McGovern ME, Berra K, Guyton JR, Kwiterovich PO, Harper WL, Toth PD, Favrot LK, Kerzner B, Nash SD, Bays HE, Simmons PD. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol; 2002; 89:672-8.
139. Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T. Fibrates downregulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood; 2003;101:545-51.
140. Rizos E, Kostoula A, Elisaf M, Mikhailidis DP. Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology; 2002;53:273-7.
141. Jonkers IJ, Mohrschladt MF, WestendorpRG, van der Laarse A, Smelt AH. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med; 2002;112:275-80.
142. Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, Hradec J. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial-FAT). Cardiovasc Res; 2001;52:290-8.
143. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation; 2002;106:679-84.
144. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol; 2003; 42:1757-63.
145. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation; 2000; 101:235-8.
146. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensinconverting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med; 2000;342:145-53.
147. Hernandez-Presa MA, Bustos C, Ortego M, Tunon J, Ortega L, Egido J. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB- dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol; 1998;153:1825-37.
148. PERTINENT-perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA studyx. Cardiovasc Drugs Ther; 2003;17:83-91.
149. Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D, Mohanty P, Tripathy D, Garg R. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab; 2003;88:4496-501.
150. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA; 2001;286:954-9.
151. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, Michel B, Luscher TF, Noll G, Ruschitzka F. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation; 2003;107:405-9.
152. Title LM, Giddens K, McInerney MM, McQueen MJ, Nassar BA. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol; 2003;42:1747-53.
153. Altman R, Luciardi HL, Muntaner J, Del Rio F, Berman SG, Lopez R, Gonzalez C. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study. Circulation; 2002;106:191-5.
154. Versaci F, Gaspardone A, Tomai F, Ribichini F, Russo P, Proietti I, Ghini AS, Ferrero V, Chiariello L, Gioffre PA, Romeo F, Crea F. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol; 2002;40:1935-42.
155. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C- reactive protein. Circulation; 1999;100:713-6.
156. Manns PJ, Williams DP, Snow CM, Wander RC. Physical activity, body fat, and serum Creactive protein in postmenopausal women with and without hormone replacement. Am J Human Biol; 2003;15:91-100.
157. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR, Bunch TJ, Allen A, Trehan S, Nielson C. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation; 2000;102:1755-60.
158. O’Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, Fisher MR, Cook TD. Azithromycin for the secondary prevention of coronary heart disease events:the WIZARD study: a randomized controlled trial. Jama; 2003;290:1459-66.
159. Bhatt DL. Inflammation and restenosis - is there a link?. Am Heart J; 2004;147:945-7.
160. Horvath C, Welt FG, Nedelman M, Rao P, Rogers C. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ Res; 2002;90:488-94.
161. Wang K, Zhou Z, Zhou X, Tarakji K, Topol EJ, Lincoff AM. Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model. J Am Coll Cardiol; 2001;38:577-82.
162. Madsen T, Skou HA, Hansen VE, Fog L, Christensen JH, Toft E, Schmidt EB. C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. Am J Cardiol; 2001; 88:1139-42.
163. Bruunsgaard H, Poulsen HE, Pedersen BK, Nyyssonen K, Kaikkonen J, Salonen JT. Longterm combined supplementations with alpha-tocopherol and vitamin C have no detectable anti-inflammatory effects in healthy men. J Nutr; 2003;133:1170-3.
164. Engler MM, Engler MB, Malloy MJ, Chiu EY, Schloetter MC, Paul SM, Stuehlinger M, Lin KY, Cooke JP, Morrow JD, Ridker PM, Rifai N, Miller E, Witztum JL, Mietus-Snyder M. Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia:Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation; 2003; 108:1059-63.
165. Brook RD, Brook JR, Rajagopalan S. Air pollution: the “Heart” of the problem. Curr Hypertens Rep; 2003;5:32-9.
166. Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of Creactive protein. Circulation; 2003;107:443-7.
167. Sierksma A, van der Gaag MS, Kluft C, Hendriks HF. Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels; a randomized, diet-controlled intervention study. Eur J Clin Nutr; 2002;56:1130-6.
168. Chrysohoou C, Panagiotakos DB, Pitsavos C, Skoumas J, Toutouza M, Papaioannou I, Toutouzas PK, Stefanadis C. Effects of chronic alcohol consumption on lipid levels, inflammatory and haemostatic factors in the general population: the ‘ATTICA’ Study. J Cardiovasc Risk; 2003;10:355-61.
169. Danner M, Kasl SV, Abramson JL, Vaccarino V. Association between depression and elevated C-reactive protein. Psychosom Med; 2003;65:347-56.
170. Ladwig KH, Marten-Mittag B, Lowel H, Doring A, Koenig W. Influence of depressive mood on the association of CRP and obesity in 3205 middle aged healthy men. Brain Behav Immun; 2003;17:268-75.
171. Berger P, McConnell JP, Nunn M, Kornman KS, Sorrell J, Stephenson K, Duff GW. Creactive protein levels are influenced by common IL-1 gene variations. Cytokine 2002;17:171-4.
172. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A, Sharma P, Lowe GD, World MJ, Humphries SE, Hingorani AD. Human CRP Gene Polymorphism Influences CRP Levels: Implications for the Prediction and Pathogenesis of Coronary Heart Disease. Arterioscler Thromb Vasc Biol; 2003;23:2063-9.
173. Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun; 2002;3:14-9.
174. Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of Creactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab; 2003;88:255-9.
175. Gaudino M, Andreotti F, Zamparelli R, Di Castelnuovo A, Nasso G, Burzotta F, Iacoviello L, Donati MB, Schiavello R, Maseri A, Possati G. The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation; 2003;108 Suppl 1:II195-9.
176. Girndt M, Kaul H, Sester U, Ulrich C, Sester M, Georg T, Kohler H. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int; 2002;62:949-55.
177. Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G, Bonafe M, Cavallone L, Marchegiani F, Olivieri F, Franceschi C, Caruso C. Inflammation, genetics, and longevity: further studies on the protective effects in men of IL-10 -1082 promoter SNP and its interaction with TNF-alpha -308 promoter SNP. J Med Genet; 2003;40:296-9.
178. Pecoits-Filho R, Stenvinkel P, Marchlewska A, Heimburger O, Barany P, Hoff CM, Holmes CJ, Suliman M, Lindholm B, Schalling M, Nordfors L. Afunctional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl 2003:S172-6.
179. Marculescu R, Mlekusch W, Exner M, Sabeti S, Michor S, Rumpold H, Mannhalter C, Minar E, Wagner O, Schillinger M. Interleukin-1 cluster combined genotype and restenosis after balloon angioplasty. Thromb Haemost; 2003;90:491-500.
180. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, Mehrabian M. Arachidonate 5-Lipoxygenase Promoter Genotype, Dietary Arachidonic Acid, and Atherosclerosis. N Engl J Med; 2004;350:29-37.
181. De Caterina R, Zampolli A. From Asthma to Atherosclerosis - 5-Lipoxygenase, Leukotrienes, and Inflammation. N Engl J Med; 2004;350:4-7.